We are live on ! Find out more

IQVIA

IQV

Market cap $45.3B

275.06 USD

-3.98

1.43%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

274.40

-0.66

0.24%

1 day

-1.43%

5 days

-0.54%

1 month

2.26%

3 months

11.11%

6 months

75.58%

Year to date

22.05%

1 year

26.27%

5 years

5.22%

10 years

283.41%

About: Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.

Employees: 95,000

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 52.9%

Neutral 41.2%

Negative 5.9%

Artisan Global Value Fund Q3 2026 Portfolio Discussion

US government debt-to-GDP exceeds 120%, while annual interest payments now surpass the budget for national defense. Our three best-performing stocks this quarter were Meta, IQVIA and Shell. Our three largest detractors this quarter were Danone, Heidelberg and Samsung Electronics.

Artisan Global Value Fund Q3 2026 Portfolio Discussion

Zacks Investment Research

Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA NYSE: IQV reported third-quarter results that exceeded the high end of its guidance ranges, supported by accelerating organic growth in its Commercial Solutions and R&D Solutions businesses, higher clinical win rates and strong free cash flow.

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA Holdings Inc. (IQV) Q3 2026 Earnings Call Transcript

IQVIA Holdings Inc. (IQV) Q3 2026 Earnings Call Transcript

IQVIA Holdings Inc. (IQV) Q3 2026 Earnings Call Transcript

Zacks Investment Research

IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y

IQV's Q3'26 earnings beat estimates as revenues rise 8% y/y, led by strong clinical demand, robust R&D bookings and improved execution, prompting a view hike.

IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y

Zacks Investment Research

IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates

IQVIA Holdings (IQV) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $3 per share a year ago.

IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates

IQVIA Reports Third-Quarter 2026 Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30, 2026. Year-Over-Year Comparisons As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance eff.

IQVIA Reports Third-Quarter 2026 Results

Zacks Investment Research

IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know

IQV is poised for y/y revenue and earnings growth in Q3, driven by stronger clinical research demand, solid bookings, AI adoption and operational efficiencies.

IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know

IQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires Execution

IQVIA Holdings (IQV) is rated Buy, supported by strong Q2 results and a robust R&D bookings recovery. Q2 revenue grew 8.7% to $4.37B, with adjusted EPS up 12.1% and R&D net new bookings surging 19% to $3.15B. Commercial Solutions delivered 8.6% revenue growth, with AI adoption and data assets driving margin expansion and cross-selling opportunities.

IQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires Execution

Zacks Investment Research

IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?

See News Rankings

Price charts implemented using Lightweight Charts™